Related Experiment Video
Updated: Nov 17, 2025
Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions
Published on: April 21, 2016
APOA1: a Protein with Multiple Therapeutic Functions
Blake J Cochran1, Kwok-Leung Ong1, Bikash Manandhar1
1Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Sydney, Level 4E Wallace Wurth Building, Kensington, New South Wales, 2052, Australia.
Insights
Apolipoprotein A1 (APOA1), a key component of HDL, shows significant therapeutic potential beyond heart health. Emerging research highlights its benefits in various diseases, with new peptide and synthetic HDL therapies under development.
Area of Science:
- Cardiovascular Science
- Biochemistry
- Therapeutics
Background:
- Apolipoprotein A1 (APOA1) is the primary apolipoprotein in high-density lipoproteins (HDLs).
- APOA1 possesses well-established cardioprotective functions.
- Recent discoveries reveal additional beneficial roles for APOA1.
Purpose of the Study:
- To review the therapeutic potential of Apolipoprotein A1 (APOA1).
- To explore APOA1's functions across multiple disease states.
- To discuss emerging APOA1-based therapeutic strategies.
Main Methods:
- Literature review of recent findings on APOA1 functions.
- Analysis of therapeutic applications in various diseases.
- Examination of APOA1-mimicking peptides and reconstituted HDL (rHDL).
Main Results:
- Growing evidence supports APOA1's beneficial roles in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders.
- Development of clinically relevant peptides and synthetic rHDL preparations.
- These agents are designed to replicate the functions of full-length APOA1.
Conclusions:
- Apolipoprotein A1 (APOA1) is a multifunctional apolipoprotein with broad therapeutic potential.
- Clinical translation hinges on the efficacy and bioavailability of novel APOA1-based therapies.
- Ongoing investigations focus on peptides and synthetic rHDL for diverse disease treatments.
Purpose Of The Review:
Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states.
Recent Findings:
Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1. APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.
Related Concept Videos
01:25Aquaporins
01:30Apoptosis
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...